69 related articles for article (PubMed ID: 8152306)
1. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I.
Edouard E; Londos-Gagliardi D; Busetta B; Geoffre S; Dalbon P; Moreau JP; Guillemain B
Leukemia; 1994 Apr; 8 Suppl 1():S65-7. PubMed ID: 8152306
[TBL] [Abstract][Full Text] [Related]
2. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.
Londos-Gagliardi D; Dalibart R; Geoffre S; Dalbon P; Pouliquen JF; Georges-Courbot MC; Sainte-Foie S; Hajjar C; Georges AJ; Moreau JP; Guillemain B
AIDS Res Hum Retroviruses; 1996 Jul; 12(10):941-50. PubMed ID: 8798979
[TBL] [Abstract][Full Text] [Related]
4. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
5. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
6. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
[TBL] [Abstract][Full Text] [Related]
7. Antigenic variability of an immunodominant region (239-261) of the surface glycoprotein of HTLV-I.
Londos-Galgliardi D; Dalibart R; Goetz M; Dalbon P; Guillemain B
Leukemia; 1997 Apr; 11 Suppl 3():17-20. PubMed ID: 9209283
[TBL] [Abstract][Full Text] [Related]
8. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
[TBL] [Abstract][Full Text] [Related]
9. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
[TBL] [Abstract][Full Text] [Related]
10. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states.
Astier-Gin T; Portail JP; Londos-Gagliardi D; Moynet D; Blanchard S; Dalibart R; Pouliquen JF; Georges-Courbot MC; Hajjar C; Sainte-Foie S; Guillemain B
J Infect Dis; 1997 Mar; 175(3):716-9. PubMed ID: 9041352
[TBL] [Abstract][Full Text] [Related]
12. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
14. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
15. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
17. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
19. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
Jacobson S; Reuben JS; Streilein RD; Palker TJ
J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
